Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Synthetic marijuana reduces agitation in patients with Alzheimer’s

17.11.2003


Reduction of agitation leads to less stress for caregiver; better care for patient



Results from a Phase II, multi-center study found dronabinol, a synthetic version of the active ingredient in marijuana, reduces agitation in patients with Alzheimer’s disease. In addition, the research concluded that reduced agitation may contribute to the relief of caregiver burden associated with the condition. The findings were presented at the American Society of Consultant Pharmacists’ 34th annual meeting.

"Our results show dronabinol is an effective treatment for behavioral agitation in patients with Alzheimer’s and may ultimately help reduce the stress often experienced by caregivers," said geriatrician Joel S. Ross, M.D. a member of the teaching faculty at Monmouth Medical Center and the lead investigator in the study. "While difficult for the patient, the effects of agitation can greatly impact the emotional and physical health of family members and caregivers. By reducing patients’ agitation, caregivers are able to focus more time and energy on their patients’ overall wellbeing."


Dronabinol, marketed as Marinol, is synthetic delta-9-tetrahydrocannabinol (delta-9-THC). Delta-9-THC also is a naturally occurring component of Cannabis sativa L (marijuana). Dronabinol has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of anorexia in patients with HIV/AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy. Recent clinical tests also have examined dronabinol’s potential to relieve symptoms of multiple sclerosis.1

Agitation is the most common behavioral management problem in patients with Alzheimer’s and affects an estimated 75 percent of people with the disease. It may lead to a variety of symptoms ranging from physical and/or verbal abusive postures, physically non-aggressive conduct including pacing and restlessness, as well as verbally disturbed behaviors such as screaming and repetitive requests for attention.

More than 80 percent of caregivers report they frequently experience high levels of stress, and nearly half say they suffer from depression, according to the Alzheimer’s Association.

The Phase II, open label, randomized, parallel-group study involved 54 community-dwelling patients at two sites, all who demonstrated behavioral agitation (mean age = 81). All patients were over the age of 50 years and met DSM-IV criteria for dementia related to Alzheimer’s. The Mini-Mental State Exam (MMSE) and the Cohen-Mansfield Agitation Inventory (CMAI) were used to measure severity of Alzheimer’s disease and agitation level, respectively. Following a one-week qualifying period to evaluate the degree of agitation, patients were screened on Day 0, evenly randomized to one of two treatment groups (dronabinol 2.5 mg bid or dronabinol 5 mg bid) on Day 7, and returned for clinic visits on Day 21, Day 35 and Day 63. The primary efficacy measurement was the CMAI, a 38-item rating scale that evaluates the prevalence of pathological and disruptive behaviors. The secondary efficacy measurements were the Caregiver’s Burden Inventory (CBI), CGI Severity of Alzheimer’s disease (CGI-S AD), Instrumental Activities of Daily Living Scale (IADL) and MMSE. Evaluation at nine weeks found significant reductions of CMAI scores in both groups. There also was a trend toward a decrease in CBI scores and increase in IADL scores in both groups, without a statistical difference between the two doses. The 5 mg bid group experienced a trend toward a decrease in CGI-S AD scores.

Doses could be adjusted during the study, allowing for a patient to receive both doses of the medication and be included in both groups at the time of evaluation for efficacy and adverse events. Adverse events experienced by more the five percent of patients involved in the study included abnormal gait, accidental injury, agitation, anxiety, asthenia, dizziness, somnolence, spontaneous bone fracture and vomiting. Two deaths occurred in the patient population, but investigators determined both were unrelated to the medication.

Monmouth Medical Center, an affiliate of the Saint Barnabas Health Care System, is a 527-bed community teaching hospital located in Long Branch, NJ. For two decades, Monmouth Medical Center’s geriatric program has been a recognized leader in the development of unique health care services for seniors. In 1982, a multidisciplinary geriatric team was established in response to the growing needs of older adults. Today, the Greenwall Geriatric Program at Monmouth coordinates health and social services for the elderly and their families in a community-teaching-hospital environment.


1Zajicek, J. The Lancet, Nov. 8, 2003: vol 263;pp 1517-1526.

Kathleen Horan | EurekAlert!

More articles from Health and Medicine:

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Collapse of the European ice sheet caused chaos

27.06.2017 | Earth Sciences

NASA sees quick development of Hurricane Dora

27.06.2017 | Earth Sciences

New method to rapidly map the 'social networks' of proteins

27.06.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>